Study of Tesetaxel in Japanese Patients With Solid Tumors

Genta Incorporated12 enrolled

Overview

Tesetaxel is an orally active tubulin-binding inhibitor of the taxane class. Evaluation of tesetaxel in Japanese patients has been limited. This study is being conducted to determine the maximum tolerated dose and safety of tesetaxel administered orally once every 21 days to Japanese patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Solid Tumors

Interventions

TesetaxelDRUG

The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Primary inclusion criteria: * At least 20 years of age * Morphologic or cytologic confirmation of an advanced or metastatic solid tumor malignancy, not to include lymphoma, for which no standard therapy exists or for which resistance or intolerance to standard therapy has developed * ECOG performance status not more than 1 * Adequate bone marrow, hepatic, and renal function * Willing to remain hospitalized for at least 10 days following tesetaxel administration in Cycle 1 * At least 4 weeks and recovery from effects of prior surgery or other therapy with an approved or investigational agent, with resolution of any toxicity to not more than Grade 1 Primary exclusion criteria: * Brain metastasis or leptomeningeal disease * Significant medical disease other than cancer * Neuropathy greater than Grade 1

Locations (1)

Kinki University School of Medicine

Osaka-fu, Japan

RECRUITING

Outcomes

Primary Outcomes

Maximum tolerated dose in mg/m2 based on the dose-limiting adverse events that occur

Time frame: First cycle (expected to be 21 days, including the day of first dose of tesetaxel followed by a rest period)

Secondary Outcomes

Dose-limiting toxicities (adverse events that result in a reduction in the dose of tesetaxel in the dose-escalation scheme)

Time frame: First cycle (expected to be 21 days, including the day of first dose of tesetaxel followed by a rest period)

Percentage of patients with adverse events

Time frame: Through 30 days after the last dose of tesetaxel

Tumor response rate

Time frame: After Cycle 2 (expected to be after Day 42 counting from the date of first dose of tesetaxel)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.